Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Ahead of Print

Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment

 Department of Medical Oncology, SBU Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey

Correspondence Address:
Sema Turker,
Department of Medical Oncology, SBU Diskapi Yildirim Beyazit Training and Research Hospital, Ziraat Mh. Sehit Omer Halisdemir Cd., 06110 Altindag, Ankara
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_343_17

Anti-epidermal growth factor receptor (EGFR) antibodies are mainly used in the treatment of advanced stages of solid tumors as a targeted therapy to inhibit tumor proliferation. They cause many dermatological adverse reactions through inhibition of EGFR pathway in the skin. A 39-year-old female patient diagnosed with metastatic colon adenocarcinoma received oxaliplatin, fluorouracil, and folinic acid regimen with cetuximab. The patient noticed increase in fairy hair especially at facial area as well as in the whole body beginning after the first few cycles of treatment, after 3 months. Obvious hypertrichosis, androgenic alopecia, and trichomegaly were observed. Blood tests for androgenetic alopecia and hirsutism were studied. Hormonal levels were in normal range. Upper abdominal imaging to rule out any adrenal lesion was also normal. Previous studies reported found that cetuximab may cause alopecia, hypertrichosis on face and body, and trichomegaly. We have not encountered a combination of hypertrichosis, androgenic type alopecia, and trichomegaly in the literature.

Print this article
  Search Pubmed for
    -  Turker S
    -  Cilbir E
    -  Karacin C
    -  Altinbas M
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded246    

Recommend this journal